Why NASDAQ:CPRX qualifies as a high growth stock.

Groth investors are looking for stocks showing high revenue and EPS growth. We will have a look here to see if CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) is suited for growth investing. Investors should of course do their own research, but we spotted CATALYST PHARMACEUTICALS INC showing up in our CANSLIM growth screen, so it may be worth spending some more time on it.

What matters for canslim investors.

• CATALYST PHARMACEUTICALS INC has demonstrated consistent growth in its earnings per share (EPS) from one quarter to another (Q2Q), with a 221.0% increase. This indicates improving financial performance and the company's effective management of its operations.
• CATALYST PHARMACEUTICALS INC has achieved significant quarter-to-quarter (Q2Q) revenue growth of 25.33%, signaling its ability to capture market opportunities and drive top-line expansion. This growth underscores the company's effective execution and its potential for continued success.
• The EPS of CATALYST PHARMACEUTICALS INC has shown consistent growth over a 3-year period, indicating the company's ability to generate increasing earnings over time.
• The Return on Equity (ROE) of CATALYST PHARMACEUTICALS INC stands at 21.61%, reflecting the company's strong profitability and effective utilization of shareholder equity. This metric signifies the company's ability to generate returns for its investors.
• CATALYST PHARMACEUTICALS INC has maintained a healthy Relative Strength (RS) over the analyzed period, with a current 90.61 rating. This demonstrates the stock's ability to outperform its peers and indicates its competitive positioning. CATALYST PHARMACEUTICALS INC is well-positioned for potential price growth opportunities.
• With a Debt-to-Equity ratio at 0.0, CATALYST PHARMACEUTICALS INC showcases its prudent financial management. The company's balanced approach between debt and equity reflects its commitment to maintaining a stable capital structure.
• CATALYST PHARMACEUTICALS INC exhibits a favorable ownership structure, with an institutional shareholder ownership of 83.84%. This signifies a diverse investor base, which can contribute to a more stable and efficient market for the stock.

Technical analysis of NASDAQ:CPRX

ChartMill assigns a proprietary Technical Rating to each stock. The score is computed daily by evaluating various technical indicators and properties. The score ranges from 0 to 10.

Taking everything into account, CPRX scores 10 out of 10 in our technical rating. Both in the recent history as in the last year, CPRX has proven to be a steady performer, scoring decent points in every aspect analyzed.

• The short term is neutral, but the long term trend is still positive. Not much to worry about for now.
• When comparing the yearly performance of all stocks, we notice that CPRX is one of the better performing stocks in the market, outperforming 90% of all stocks. We also observe that the gains produced by CPRX over the past year are nicely spread over this period.
• CPRX is part of the Biotechnology industry. There are 572 other stocks in this industry. CPRX outperforms 88% of them.
• CPRX is currently trading in the upper part of its 52 week range. The S&P500 Index however is currently trading near a new high, so CPRX is lagging the market slightly.
• In the last month CPRX has a been trading in the 21.69 - 24.64 range, which is quite wide. It is currently trading in the middle of this range where prices have been consolidating recently, this may present a good entry opportunity, but some resistance may be present above.

Our latest full technical report of CPRX contains the most current technical analsysis.

How does the complete fundamental picture look for NASDAQ:CPRX?

ChartMill assigns a proprietary Fundamental Rating to each stock. The score is computed daily by evaluating various fundamental indicators and properties. The score ranges from 0 to 10.

Overall CPRX gets a fundamental rating of 8 out of 10. We evaluated CPRX against 572 industry peers in the Biotechnology industry. CPRX has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. An interesting combination arises when we look at growth and value: CPRX is growing strongly while it also seems undervalued. These ratings would make CPRX suitable for value and growth and quality investing!

Check the latest full fundamental report of CPRX for a complete fundamental analysis.

More ideas for growth investing can be found on ChartMill in our CANSLIM screen.

Disclaimer

This article should in no way be interpreted as advice. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.